GlassScriptPhysician profile
John C Monteleone
NPI 1982712535
$5,633.61
in general payments reported to CMS, 2019-2025
26 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $273 · 2022: $345 · 2023: $481 · 2024: $1,790 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,275.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,037.33 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $894.88 | 2019-2025 | Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $764.68 | 2023-2025 | |
| Novo Nordisk INC | $426.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $138.63 | 2019-2020 | |
| Esperion Therapeutics, INC. | $137.77 | 2024 | Nexletol, Nexlizet |
| Organogenesis INC. | $125.03 | 2024 | Puraply Wound Matrix |
| Abbvie INC. | $112.15 | 2024-2025 | |
| Pfizer INC. | $94.58 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $86.27 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $80.00 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $79.00 | 2019 | |
| Glaxosmithkline, LLC. | $76.76 | 2019-2020 | |
| Amgen INC. | $73.82 | 2019-2025 | Otezla, Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $32.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $31.45 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.73 | 2025 | Recorlev |
| Arbor Pharmaceuticals, INC. | $24.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.08 | 2019 | |
| Abbott Laboratories | $19.86 | 2019 | |
| Hologic Sales and Service, LLC | $16.99 | 2019 | |
| Sanofi Pasteur INC. | $15.75 | 2020 | |
| Allergan, INC. | $15.16 | 2019 | |
| Daiichi Sankyo INC. | $13.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Monteleone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.